The Influence of Lobe-based Radiotherapy Plan Optimization Method on Different Lymph Node Irradiation Schemes for Operable LA-NSCLC Patients

Author(s):  
Hengle Gu ◽  
Hongxuan Li ◽  
Xiaolong Fu ◽  
Zhiyong Xu

Abstract Purpose Various target volume delineation schemes differ greatly for stage IIIa NSCLC radiotherapy. Although tightened target volume may give patients the opportunity to receive radiotherapy, it is not absolutely safe to narrow the irradiation area. For IIIa NSCLC patients who will undergo lobectomy, a new neoadjuvant radiotherapy based on sparing preserved lung lobes may improve the dose distribution of the preserved lobe, and provide freedom for physicians in optimizing treatment strategies. Materials and methods Computed tomography imaging data of 20 IIIA- p N2 NSCLC patients were used to produce conventional IMRT(IMRT) and Preserved Lobe based IMRT(P-IMRT) plan respectively according to two different target volume delineation schemes(OPT1 and OPT2). Dose results of target coverage, Total lung, Ipsilateral lung, Preserved Total Lung, Preserved Ipsilateral Lung, Contralateral Lung, Resected Lobe and other OARs in the four groups were analyzed. Results All plans met dose limits. Lobe-based IMRT significantly reduce the irradiated dose of Lung lobes, especially Preserved Total Lung and Preserved Ipsilateral Lung, for both delineation schemes. Mean Dose of Preserved Total Lung decreased from 819.93 cGy to 690.98 cGy (OPT1) and 542.47 cGy to 469.62 cGy (OPT2), Mean Dose of Preserved Ipsilateral Lung decreased from 1282.95 cGy to 1068.55 cGy (OPT1) and 955.83 cGy to 795.97 cGy (OPT2), respectively. While the dose indices of Resected Lobe increased slightly for only about 1%. Comparing the four groups of plans, it’s more effective in optimizing the dose of lung lobes by this method for the delineation scheme with a large target volume. The lung dose metrics in P-IMRTOPT1 can be reduced to a value very close to that in IMRTOPT2, and some values are even lower than that in IMRTOPT2. Conclusion For IIIA-N2 NSCLC patients who will undergo lobectomy, no matter which target delineation scheme is chosen, preoperative neoadjuvant radiotherapy using a lobe -based planning can significantly reduce the radiation dose that preserves the lobes. Especially for the large-scale lymph node irradiation scheme, this method can also reduce the dose of preserved lung lobe to a level that is comparable to or lower than that of the conventional IMRT small-area lymph node irradiation scheme, and reduce the obstacles for clinicians in selecting the optimal individualized scheme.

2013 ◽  
Vol 8 ◽  
Author(s):  
Li-Jie Yin ◽  
Xiao-Bin Yu ◽  
Yan-Gang Ren ◽  
Guang-Hai Gu ◽  
Tian-Gui Ding ◽  
...  

Background: To investigate the utilization of PET-CT in target volume delineation for three-dimensional conformal radiotherapy in patients with non-small cell lung cancer (NSCLC) and atelectasis. Methods: Thirty NSCLC patients who underwent radical radiotherapy from August 2010 to March 2012 were included in this study. All patients were pathologically confirmed to have atelectasis by imaging examination. PET-CT scanning was performed in these patients. According to the PET-CT scan results, the gross tumor volume (GTV) and organs at risk (OARs, including the lungs, heart, esophagus and spinal cord) were delineated separately both on CT and PET-CT images. The clinical target volume (CTV) was defined as the GTV plus a margin of 6-8 mm, and the planning target volume (PTV) as the GTV plus a margin of 10-15 mm. An experienced physician was responsible for designing treatment plans PlanCT and PlanPET-CT on CT image sets. 95% of the PTV was encompassed by the 90% isodose curve, and the two treatment plans kept the same beam direction, beam number, gantry angle, and position of the multi-leaf collimator as much as possible. The GTV was compared using a target delineation system, and doses distributions to OARs were compared on the basis of dose-volume histogram (DVH) parameters. Results: The GTVCT and GTVPET-CT had varying degrees of change in all 30 patients, and the changes in the GTVCT and GTVPET-CT exceeded 25% in 12 (40%) patients. The GTVPET-CT decreased in varying degrees compared to the GTVCT in 22 patients. Their median GTVPET-CT and median GTVPET-CT were 111.4 cm3 (range, 37.8 cm3-188.7 cm3) and 155.1 cm3 (range, 76.2 cm3-301.0 cm3), respectively, and the former was 43.7 cm3 (28.2%) less than the latter. The GTVPET-CT increased in varying degrees compared to the GTVCT in 8 patients. Their median GTVPET-CT and median GTVPET-CT were 144.7 cm3 (range, 125.4 cm3-178.7 cm3) and 125.8 cm3 (range, 105.6 cm3-153.5 cm3), respectively, and the former was 18.9 cm3 (15.0%) greater than the latter. Compared to PlanCT parameters, PlanPET-CT parameters showed varying degrees of changes. The changes in lung V20, V30, esophageal V50 and V55 were statistically significant (Ps< 0.05 for all), while the differences in mean lung dose, lung V5, V10, V15, heart V30, mean esophageal dose, esophagus Dmax, and spinal cord Dmax were not significant (Ps> 0.05 for all). Conclusions: PET-CT allows a better distinction between the collapsed lung tissue and tumor tissue, improving the accuracy of radiotherapy target delineation, and reducing radiation damage to the surrounding OARs in NSCLC patients with atelectasis.


Breast Care ◽  
2020 ◽  
Vol 15 (2) ◽  
pp. 128-135
Author(s):  
Marciana Nona Duma

Background: Tremendous changes have occurred in the treatment of breast cancer. This paper reviews and unifies the available data on modern axillary management of breast cancer patients with focus on the target volume delineation for regional nodal irradiation according to the most important contouring guidelines, the European Society for Radiotherapy and Oncology (ESTRO) and the Radiation Therapy and Oncology Group (RTOG). Summary: The use of extensive radiotherapy target volumes (level I, II, III, IV) is probably not necessary for all patients to reproduce the clinical benefit shown in the available randomized trials (EORTC, MA.20, AMAROS, Z0011). Nevertheless, given the results in the MA.20 trial, where the patients received more modern systemic therapies and high irradiation doses in the medial paraclavicular region (level IV) and level II, it can be justified to include these regions completely in selected high-risk patients. Key Messages: High-tangent irradiation results in a similar dose distribution in axillary levels I and II compared to the AMAROS treatment field design in some patients. This supports earlier assumptions that irradiation may have accounted for the good results after sentinel lymph node dissection alone in the Z0011 trial. The ESTRO and RTOG clinical target volume (CTV) definitions cover sufficiently the metastatic lymph node hotspots, with a better coverage for the ESTRO CTV. Further, contouring according to the ESTRO would spare a significantly larger part of the healthy lymphatic system, making it our preferred contouring atlas. Modern radiotherapy techniques, such as deep inspiration breath hold, should be cautiously employed in patients treated according to the inclusion criteria of the Z0011 as it will result in a lower dose to the axillary levels.


Sign in / Sign up

Export Citation Format

Share Document